Literature DB >> 12609815

Myogenic responses and compliance of mesenteric and splenic vasculature in the rat.

Zoe L S Brookes1, Susan Kaufman.   

Abstract

In the rat, the spleen is a major site of fluid efflux out of the blood. By contrast, the mesenteric vasculature serves as a blood reservoir. We proposed that the compliance and myogenic responses of these vascular beds would reflect their different functional demands. Mesenteric and splenic arterioles ( approximately 150-200 microm) and venules (<250 microm) from rats anesthetized with pentobarbital sodium were mounted in a pressurized myograph. Mesenteric arterial diameter decreased from 146 +/- 6 to 133 +/- 6 microm on raising intraluminal pressures from 80 to 120 mmHg. This response was enhanced in the presence of N(omega)-nitro-l-arginine methyl ester (l-NAME; 139 +/- 6 to 112 +/- 7 microm). There was no such myogenic response in the splenic arterioles, except in the presence of l-NAME (194 +/- 4 to 164 +/- 4.2 microm). We propose that, whereas mesenteric arterioles exhibit myogenic responses, this is normally masked by NO-mediated dilation in the splenic vessels. The mesenteric venules were highly distensible (active, 184 +/- 15 to 320 +/- 30.9 microm; passive in Ca(2+)-free media, 209 +/- 31 to 344 +/- 27 microm; 4-8 mmHg) compared with the splenic vessels (active, 169 +/- 11 to 184 +/- 16 microm; passive, 187 +/- 12 to 207 +/- 17 microm). We conclude that, in response to an increase in perfusion pressure, mesenteric arterial diameter would decrease to limit the changes in flow and microvascular pressure. In addition, mesenteric venous capacitance would increase. By contrast, splenic arterial diameter would increase, while there would be little change in venous diameter. This would enhance the increase in intrasplenic microvascular pressure and increase fluid extravasation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12609815     DOI: 10.1152/ajpregu.00411.2002

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  7 in total

Review 1.  Renal autoregulation in health and disease.

Authors:  Mattias Carlström; Christopher S Wilcox; William J Arendshorst
Journal:  Physiol Rev       Date:  2015-04       Impact factor: 37.312

2.  Constriction of rat extra-splenic veins to lipopolysaccharide involves endothelin-1.

Authors:  Arnaud Mansart; Lewis J Ruff; Mark P Ariaans; Jonathan J Ross; Charles S Reilly; Nicola J Brown; Susan Kaufman; Zoë L S Brookes
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-04-16       Impact factor: 3.000

3.  Ascorbate improves circulation in postural tachycardia syndrome.

Authors:  Julian M Stewart; Anthony J Ocon; Marvin S Medow
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-05-27       Impact factor: 4.733

4.  Nitric oxide blunts myogenic autoregulation in rat renal but not skeletal muscle circulation via tubuloglomerular feedback.

Authors:  Armin Just; William J Arendshorst
Journal:  J Physiol       Date:  2005-10-13       Impact factor: 5.182

5.  Pkd2 mesenteric vessels exhibit a primary defect in endothelium-dependent vasodilatation restored by rosiglitazone.

Authors:  Zoë L S Brookes; Lewis Ruff; Viralkumar S Upadhyay; Linghong Huang; Sony Prasad; Tirupa Solanky; Surya M Nauli; Albert C M Ong
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-10-26       Impact factor: 4.733

6.  The nociceptin/orphanin FQ receptor antagonist UFP-101 reduces microvascular inflammation to lipopolysaccharide in vivo.

Authors:  Zoë L S Brookes; Emily N Stedman; Nicola J Brown; Christopher P Hebbes; Remo Guerrini; Girolamo Calo; Charles S Reilly; David G Lambert
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

7.  Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding.

Authors:  Janet Chamberlain; Sheila Francis; Zoe Brookes; Gary Shaw; Delyth Graham; Nicholas J Alp; Steven Dower; David C Crossman
Journal:  PLoS One       Date:  2009-04-06       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.